Abstract:Combined treatment targeting mitochondria may improve the efficacy of lung cancer chemoprevention. Here, mitochondria-targeted honokiol (Mito-HNK), an inhibitor of mitochondrial complex I and STAT3 phosphorylation, and mitochondria-targeted lonidamine (Mito-LND), an inhibitor of mitochondrial complexes I/II and AKT/mTOR/p70S6K signaling, were evaluated for their combinational chemopreventive efficacy on mouse lung carcinogenesis. All chemopreventive treatments began one-week post-carcinogen treatment and continued daily for 24 weeks. No evidence of toxicity (including liver toxicity) was detected by monitoring serum levels of alanine aminotransferase and aspartate aminotransferase enzymes. Mito-HNK or Mito-LND treatment alone reduced tumor load by 56% and 48%, respectively, whereas the combination of Mito-HNK and Mito-LND reduced tumor load by 83%. To understand the potential mechanism(s) of action for the observed combinatorial effects, single-cell RNA sequencing was performed using mouse tumors treated with Mito-HNK, Mito-LND, and their combination. In lung tumor cells, Mito-HNK treatment blocked the expression of genes involved in mitochondrial complex ǀ, oxidative phosphorylation, glycolysis, and STAT3 signaling. Mito-LND inhibited the expression of genes for mitochondrial complexes I/II, oxidative phosphorylation, and AKT/mTOR/p70S6K signaling in lung tumor cells. In addition to these changes, a combination of Mito-HNK with Mito-LND decreased arginine and proline metabolism, N-glycan biosynthesis, and tryptophan metabolism in lung tumor cells. Our results demonstrate that Mito-LND enhanced the antitumor efficacy of Mito-HNK, where both compounds inhibited common targets (oxidative phosphorylation) as well as unique targets for each agent (STAT3 and mTOR signaling). Therefore, the combination of Mito-HNK with Mito-LND may present an effective strategy for lung cancer chemoprevention.

Mitochondrion-targeted Platinum Complexes Suppressing Lung Cancer Through Multiple Pathways Involving Energy Metabolism

Multi-omics analysis revealed the mitochondrial-targeted drug combination to suppress the development of lung cancer

A Mitochondrion-Targeting Copper Complex Exhibits Potent Cytotoxicity Against Cisplatin-Resistant Tumor Cells Through Multiple Mechanisms of Action

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer

Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion‐Targeted Platinum(II) Complex

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Chemoprevention of Lung Cancer with a Combination of Mitochondria-Targeted Compounds

DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer Cells

Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function

Regulating Tumor Glycometabolism and Immune Microenvironment by Inhibiting Lactate Dehydrogenase with Platinum(IV) Complexes

Assessing Impact of Platinum Complexes on Mitochondrial Functions.

Targeting Energy Metabolism by a Platinum(IV) Prodrug As an Alternative Pathway for Cancer Suppression.

DNA topoisomerases as additional targets for anticancer monofunctional platinum( ii ) complexes

Regulating Tumor Glycometabolism and the Immune Microenvironment by Inhibiting Lactate Dehydrogenase with Platinum(iv) Complexes

Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction

Novel Mitochondrion-Targeting Copper(ii) Complex Induces HK2 Malfunction and Inhibits Glycolysis Via Drp1-mediating Mitophagy in HCC

Dual-target platinum(IV) complexes exhibit antiproliferative activity through DNA damage and induce ER-stress-mediated apoptosis in A549 cells

Development of Cu(II) 4-Hydroxybenzoylhydrazone Complexes That Induce Mitochondrial DNA Damage and Mitochondria-Mediated Apoptosis in Liver Cancer

Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199